结直肠癌预后生物标志物研究进展

doi:10.16138/j.1673-6087.2024.05.10

摘要/Abstract

摘要：

结直肠癌(colorectal carcinoma, CRC)是全球最常见的消化系统恶性肿瘤之一，流行病学统计显示，2020年全球CRC发病数居所有癌症发病数第3位，死亡率居第2位，其发病率增加的原因仍无明确定论，目前学界认为CRC的发生是一个多因素、多步骤的慢性过程，但因其起病隐匿，早期发现率低，多数患者因出现症状而就诊时多已处于疾病中晚期，导致其预后不良。我国CRC 5年平均生存率为56.9%，在周边亚太地区中处最低位，已对我国公民的生命健康造成巨大威胁，因而进一步了解CRC预后生物标志物对于推动CRC个体化治疗，以提高CRC患者的生存率与生存质量有重要作用。本文就CRC预后生物标志物研究新进展作一综述，以期对未来的CRC治疗有所启示。

关键词: 结直肠癌, 预后, 生物标志物, 监测

Abstract:

Colorectal cancer (CRC) is one of the most common malignant tumors of digestive system in the world. Epidemiological statistics showed that the global incidence of CRC ranked third among all cancer types and its mortality rate ranked second in 2020, while the reasons for the increased incidence are still not clear. At present, it is believed that the occurrence of CRC is a multi-factor and multi-step chronic process. Because the onset of CRC is insidious and the early detection rate is low, most patients are diagnosed in the middle and late stage as symptoms develop, which leads to poor prognosis. The average 5-year survival rate of CRC in China was 56.9%, which was the lowest among surrounding Asia-Pacific countries. CRC has become a huge threat to the life and health of Chinese citizens. Therefore, further understanding of prognosis biomarkers of CRC are important in promoting individualized treatment and improving the survival rate and quality of life in CRC patients. This article reviews the research progress on prognostic biomarkers for CRC to provide some inspiration for future treatment of CRC.

Key words: Colorectal cancer, Prognosis, Biomarkers, Monitoring

中图分类号:

R735.2

王虹晓, 苏琪莹, 阎骅. 结直肠癌预后生物标志物研究进展[J]. 内科理论与实践, 2024, 19(05): 337-341.

WANG Hongxiao, SU Qiying, YAN Hua. Research progress on prognostic biomarkers for colorectal cancer[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(05): 337-341.

参考文献 38

[1]	周雄, 胡明, 李子帅, 等. 2020年全球及中国结直肠癌流行状况分析[J]. 海军军医大学学报, 2022, 43(12):1356-1364.
[2]	Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5):e555-e567. doi: 10.1016/S2214-109X(18)30127-X pmid: 29653628
[3]	Magaji BA, Moy FM, Roslani AC, et al. Survival rates and predictors of survival among colorectal cancer patients in a Malaysian tertiary hospital[J]. BMC Cancer, 2017, 17(1):339. doi: 10.1186/s12885-017-3336-z pmid: 28521746
[4]	Gao JJ, Wang YW, Li Y, et al. Performance of circulating methylated Septin9 gene DNA in diagnosis and recurrence monitoring of colorectal cancer in Western China[J]. Clin Chim Acta, 2022, 537:118-126.
[5]	de Vos L, Jung M, Koerber RM, et al. Treatment response monitoring in patients with advanced malignancies using cell-ree SHOX2 and SEPT9 DNA methylation in blood: an observational prospective study[J]. J Mol Diagn, 2020, 22(7):920-933.
[6]	Krokowski S, Mostowy S. Bacterial cell division is recognized by the septin cytoskeleton for restriction by autophagy[J]. Autophagy, 2019, 15(5):937-939. doi: 10.1080/15548627.2019.1586499 pmid: 30857451
[7]	Zeng Y, Cao Y, Liu L, et al. SEPT9_i1 regulates human breast cancer cell motility through cytoskeletal and RhoA/FAK signaling pathway regulation[J]. Cell Death Dis, 2019, 10(10):720. doi: 10.1038/s41419-019-1947-9 pmid: 31558699
[8]	Rao S, Chiu TP, Kribelbauer JF, et al. Systematic prediction of DNA shape changes due to CpG methylation explains epigenetic effects on protein-DNA binding[J]. Epigenetics Chromatin, 2018, 11(1):6. doi: 10.1186/s13072-018-0174-4 pmid: 29409522
[9]	Masalmeh RHA, Taglini F, Rubio-Ramon C, et al. De novo DNA methyltransferase activity in colorectal cancer is directed towards H3K36me3 marked CpG islands[J]. Nat Commun, 2021, 12(1):694. doi: 10.1038/s41467-020-20716-w pmid: 33514701
[10]	Sun J, Zheng MY, Li YW, et al. Structure and function of Septin 9 and its role in human malignant tumors[J]. World J Gastrointest Oncol, 2020, 12(6):619-631.
[11]	Liu W, Hu P, Liu J, et al. mSEPT9 can monitor the response and predict the prognosis of stage Ⅳ colorectal cancer patients with liver metastasis undergoing potentially curative surgery[J]. J Surg Res, 2021, 267:485-494.
[12]	Karimi N, Ali Hosseinpour Feizi M, Safaralizadeh R, et al. Serum overexpression of miR-301a and miR-23a in patients with colorectal cancer[J]. J Chin Med Assoc, 2019, 82(3):215-220. doi: 10.1097/JCMA.0000000000000031 pmid: 30913118
[13]	Wang S, Zhang Z, Gao Q. Transfer of microRNA-25 by colorectal cancer cell-derived extracellular vesicles facilitates colorectal cancer development and metastasis[J]. Mol Ther Nucleic Acids, 2020, 23:552-564.
[14]	Kaur S, Bronson SM, Pal-Nath D, et al. Functions of thrombospondin-1 in the tumor microenvironment[J]. Int J Mol Sci, 2021, 22(9):4570.
[15]	Kilikevicius A, Meister G, Corey DR. Reexamining assumptions about miRNA-guided gene silencing[J]. Nucleic Acids Res, 2022, 50(2):617-634.
[16]	Zhang N, Hu X, Du Y, et al. The role of miRNAs in colorectal cancer progression and chemoradiotherapy[J]. Biomed Pharmacother, 2021, 134:111099. doi: 10.1016/j.biopha.2020.111099 pmid: 33338745
[17]	Zhang L, Liu Y, Chen XG, et al. MicroRNA expression profile in chronic nonbacterial prostatitis revealed by next-generation small RNA sequencing[J]. Asian J Androl, 2019, 21(4):351-359. doi: 10.4103/aja.aja_97_18 pmid: 30604696
[18]	Dhawan A, Scott JG, Harris AL, et al. Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors[J]. Nat Commun, 2018, 9(1):5228. doi: 10.1038/s41467-018-07657-1 pmid: 30531873
[19]	Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the rosetta stone of therapy resistance[J]. Cancer Cell, 2020, 37(4):471-484. doi: S1535-6108(20)30147-1 pmid: 32289271
[20]	Iqbal MA, Arora S, Prakasam G, et al. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance[J]. Mol Aspects Med, 2019, 70:3-20. doi: S0098-2997(18)30065-7 pmid: 30102929
[21]	Wang LQ, Yu P, Li B, et al. miR-372 and miR-373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways[J]. Mol Oncol, 2018, 12(11):1949-1964.
[22]	Tsiakanikas P, Kontos CK, Kerimis D, et al. High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease[J]. Clin Chem Lab Med, 2018, 56(6):990-1000. doi: 10.1515/cclm-2017-0430 pmid: 29688883
[23]	Tian F, Wang P, Lin D, et al. Exosome-delivered miR-221/222 exacerbates tumor liver metastasis by targeting SPINT1 in colorectal cancer[J]. Cancer Sci, 2021, 112(9):3744-3755.
[24]	Liu H, Liu Y, Sun P, et al. Colorectal cancer-derived exosomal miR-106b-3p promotes metastasis by down-regulating DLC-1 expression[J]. Clin Sci (Lond), 2020, 134(4):419-434. doi: 10.1042/CS20191087 pmid: 32065214
[25]	Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages Ⅰ to Ⅲ colorectal cancer[J]. JAMA Oncol, 2019, 5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528
[26]	Garbers C, Heink S, Korn T, et al. Interleukin-6: designing specific therapeutics for a complex cytokine[J]. Nat Rev Drug Discov, 2018, 17(6):395-412. doi: 10.1038/nrd.2018.45 pmid: 29725131
[27]	Osumi H, Shinozaki E, Yamaguchi K, et al. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer[J]. Sci Rep, 2019, 9(1):17358. doi: 10.1038/s41598-019-53711-3 pmid: 31758080
[28]	Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure[J]. Nat Rev Clin Oncol, 2019, 16(7):409-424. doi: 10.1038/s41571-019-0187-3 pmid: 30796368
[29]	Wang Y, Li L, Cohen JD, et al. Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer[J]. JAMA Oncol, 2019, 5(8):1118-1123.
[30]	Taieb J, Taly V, Henriques J, et al. Prognostic value and relation with adjuvant treatment duration of ctDNA in stage Ⅲ colon cancer: a post hoc analysis of the PRODIGE-GERCOR IDEA-France trial[J]. Clin Cancer Res, 2021, 27(20):5638-5646.
[31]	Chen G, Peng J, Xiao Q, et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages Ⅱ to Ⅲ colorectal cancer[J]. J Hematol Oncol, 2021, 14(1):80.
[32]	Rossi S, Basso M, Strippoli A, et al. Are markers of systemic inflammation good prognostic indicators in colorectal cancer?[J]. Clin Colorectal Cancer, 2017, 16(4):264-274.
[33]	Dolan RD, Almasaudi AS, Dieu LB, et al. The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer[J]. J Cachexia Sarcopenia Muscle, 2019, 10(1):111-122. doi: 10.1002/jcsm.12357 pmid: 30460764
[34]	Li H, Song J, Cao M, et al. Preoperative neutrophil-to-lymphocyte ratio is a more valuable prognostic factor than platelet-to-lymphocyte ratio for nonmetastatic rectal cancer[J]. Int Immunopharmacol, 2016, 40:327-331. doi: S1567-5769(16)30388-5 pmid: 27664571
[35]	Inamoto S, Kawada K, Okamura R, et al. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study[J]. Int J Colorectal Dis, 2019, 34(7):1303-1315. doi: 10.1007/s00384-019-03316-z pmid: 31177316
[36]	Verter E, Berger Y, Perl G, et al. Neutrophil-to-lymphocyte ratio predicts recurrence pattern in patients with resectable colorectal liver metastases[J]. Ann Surg Oncol, 2021, 28(8):4320-4329.
[37]	Yasui K, Shida D, Nakamura Y, et al. Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage Ⅲ colorectal cancer patients[J]. Br J Cancer, 2021, 124(5):933-941.
[38]	毛富巍, 曹英豪, 邓胜. 基于NLR、PLR、WLR、MLR的系统炎症标志物评分与结直肠癌患者术后生存时间的相关性[J]. 华中科技大学学报(医学版), 2022, 51(2):229-234.